China’s Domestic sees Sluggish Demands while Exports Increases
Revance's Botox Rival Receives USFDA Nod
By Indu Tyagi Ketan , 19 October, 2022
DaxibotulinumtoxinA (Daxxify), Revance's long-awaited Botox rival, has officially received FDA approval, as the company is now gearing up to establish its brand. Daxxify is an intravenous neuromodulator similar to Botox; its novel peptide exchange technology temporarily eases the moderate to severe glabellar (frown) lines.
The trials revealed that a single injection had a significant anti-wrinkle impact on durational effects were proven in phase 3 trials with 4,200 treatments and 2,700 patients. The chief differentiator for Daxxify is its endurance; it can last six months and has even proven effective for up to nine months in some individuals, vis-a-vis Botox injections that last only for three months.
Daxxify was initially scheduled to receive FDA approval in November 2020, but the epidemic slowed inspection. After visiting Revance's production facility, inspectors discovered quality control and record-keeping issues. The FDA then issued Revance a detailed response letter in October of last year. Soon after, the FDA approved the changes in July after Revance resolved all five problems mentioned in the Complete Response Letter.
In a separate report, Goldman Sachs predicted that Revance's Daxxify will cost about 30% more than its competitors, even though pricing has not yet been made public. This cost considers the extended value proposition for both doctors and patients. Revance's stock rose 18% in September post the FDA's approval, which is expected to end Botox's long-standing dominance in the aesthetics industry.
FDA Approves DaxibotulinumtoxinA (Daxxify)
Latest News
China’s Domestic sees Sluggish Demands while Exports Increases
China is one of the progressing economies of this decade. The country is emerging as an international hub for electric vehicle manufacturing. The growing clean energy transition rates have strengthened its energy sector with increasing renewable…
AI and ML Helps in the Progress of Vaccines
The development of vaccines in the healthcare sector has adopted new technologies to enhance the quality and quantity over the years. The importance of significant production of vaccines comes with proper awareness among the masses. The healthcare…
Crude Oil Production in US Energy Sector Drives Employment in 2024
Employment in the energy sector continues to grow due to the transition in the energy sector in 2024. The employment energy services sector experiences a significant rate of increase in employment. It continues to grow amidst several industrial…
Big Auto and American Government Collabs to Boost Ev Production in 2024
The American government is preparing to boost electric vehicle sales soon. Therefore, the current American administration has announced it will grant USD 2 billion to the auto industry in 2024. Top car makers in the industry, such as Stellantis and…
Lack of Infrastructure Affects Electric Vehicles Sales in the European Nations
Electric vehicles are gaining momentum in the automobile market. The clean energy transition trends will also boost the demand for electric cars in 2024. A survey in 2024 shows the list of European countries in 2024. This survey shows that the lack…
Indu Tyagi Ketan
Chief Strategy Officer
